August 2026 Issue

In this issue, we explore what it takes for an adjuvant designed for one disease to earn a place in oncology, find out why a manufacturing technology built for speed may never compete on scale, and learn why technology transfer requires far more than intellectual property transfer.

"No one can know which pathogen will pose the next threat, or which platform will prove most effective."
– Robert Walker, Executive Vice President, Head of Research & Development, Novavax

"One of the most common misconceptions is that technology transfer is simply a transfer of intellectual property. It is not."
– Rajinder Suri, Chief Executive Officer, Developing Countries Vaccine Manufacturers Network (DCVMN)